TRVI Insider Trading Activity and SEC Form 4 Filings
TRVI insider trading summary
Over the past 12 months, insiders at Trevi Therapeutics, Inc. (TRVI) reported 3 sales worth $594K by 1 insider and no open-market purchases on SEC Form 4. Net insider selling was $594K.
Latest TRVI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Michael Thomas Heffernan | Insider | Sell | $276K (18,321 @ $15.09) |
| Sep 15, 2026 | Michael Thomas Heffernan | Insider | Sell | $316K (20,952 @ $15.09) |
| Sep 15, 2026 | Michael Thomas Heffernan | Insider | Sell | $2K (100 @ $15.88) |
| Mar 25, 2025 | Thomas Sciascia | Chief Scientific Officer | Sell | $17K (2,631 @ $6.60) |
| Mar 21, 2025 | Jennifer L Good | President & CEO | Sell | $35K (5,263 @ $6.58) |
| Mar 10, 2025 | Farrell Simon | Chief Commercial Officer | Sell | $518K (76,963 @ $6.73) |
| Mar 10, 2025 | Farrell Simon | Chief Commercial Officer | Sell | $31K (4,350 @ $7.15) |
| Sep 9, 2024 | Jennifer L Good | President & CEO | Sell | $6K (1,840 @ $3.04) |
| Sep 6, 2024 | Jennifer L Good | President & CEO | Sell | $13K (4,219 @ $3.03) |
| Sep 5, 2024 | Jennifer L Good | President & CEO | Sell | $125K (40,277 @ $3.11) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.